Navigation Links
Orexigen Therapeutics, Inc. Prices Offering of $100 Million of Convertible Senior Notes
Date:12/3/2013

xigen cautions you that statements included in this press release that are not a description of historical facts are forward‐looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "should," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward‐looking statements. These statements are based on the Company's current beliefs and expectations. These forward‐looking statements include statements regarding: the actual terms of the Notes, the completion, timing and size of the proposed private offering and the anticipated use of proceeds from the offering. The inclusion of forward‐looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in the Orexigen business. You are cautioned not to place undue reliance on these forward‐looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading "Risk Factors" in Orexigen's Current Report on Form 8-K filed with the Securities and Exchange Commission on December 2, 2013 and its other reports, which are available from the SEC's website (www.sec.gov). All forward‐looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.Orexigen Contact:

Media Contact: McDavid Stilwell

Denise Powell

SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Orexigen Therapeutics Prepares for the Light Study Interim Analysis Based on Direction from Data Monitoring Committee
2. Technical Study: Vertex Pharma Inc., Orexigen Therapeutics Inc., MAKO Surgical Corp., and Alere Inc.
3. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
4. Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013
5. Orexigen Therapeutics Commends the Campaign to End Obesitys Report on Long-term Returns of Obesity Prevention Policies
6. Orexigen CEO Michael Narachi Elected to PhRMA Board of Directors
7. Orexigen Therapeutics to Present at Upcoming Conferences
8. Global Aptamers Market Technology Trend Analysis Market Report 2013-2018: Therapeutics, Diagnostics, Biosensors, Biomarker/Drug Discovery & Applications
9. Acquisitions, Project Announcements & Trend Analysis News for Oxygen Biotherapeutics, Glu Mobile, Cisco Systems, Barrick Gold, CVS Caremark
10. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Trius Therapeutics, Inc. - TSRX
11. BioTech Companies in the News - Alliqua, Transition Therapeutics, Organovo, MiMedx Group, Keryx Biopharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... , Jan. 14, 2014 The largest ... research medicinal plants and therapeutic derivatives thereof has ... professionals, and researchers about the challenges of adulterated ... http://photos.prnewswire.com/prnh/20100430/DC95601LOGO ) The Society for ...
(Date:1/14/2014)... January 14, 2014 In recent years, ... and methods in product development and promotion has led ... This mistrust, fueled by concerns about the insidious impact ... reports of spectacular fines to the world’s biggest pharmas ...
(Date:1/14/2014)... 14, 2014   Kinaxis ®, provider of RapidResponse ®, ... and operations planning ( S&OP ) service, is proud to ... which will be held at the Hilton San Diego Bayfront, ... customer Elisabeth Kaszas , Director of Supply Chain at ...
(Date:1/14/2014)... During the 1600’s through the 1800’s doctors ... Plague.” In this time period, doctors did not know that ... to the death of vulnerable patients. In the same way, ... may be unwittingly transmitting herpes viruses to their patients. The ...
Breaking Biology Technology:World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... Rising star Divine Skin Inc. (DSKX), which has been expanding ... long-time leader in the cosmetics industry, to become its president. ... Divine Skin because I believe their innovative products are unmatched ... with a ,wow, factor." A dozen Divine ...
... 25, 2011 For the first time, Eli Lilly and ... to more than 800 grassroots projects across the globe and ... Foundation—doubling the value and impact of each employee,s charitable contribution. ... to offer its employees across the world a customized Lilly ...
... Sciences International, Inc. (Nasdaq: BDSI ) announced ... portion of its Phase 3 clinical trial assessing the ... of moderate to severe chronic pain, signifying completion of ... are very pleased to have brought to completion our ...
Cached Biology Technology:Robin Powell Becomes President at Biotech Leader Divine Skin (DSKX) 2Lilly Global Giving Puts Power of Philanthropy in Employees' Hands 2Lilly Global Giving Puts Power of Philanthropy in Employees' Hands 3Lilly Global Giving Puts Power of Philanthropy in Employees' Hands 4BioDelivery Sciences Announces Completion of BEMA Buprenorphine Phase 3 Chronic Pain Study 2BioDelivery Sciences Announces Completion of BEMA Buprenorphine Phase 3 Chronic Pain Study 3
(Date:7/9/2014)... with the highest distribution in the Iberian Peninsula. It ... comes into contact with the red swamp crayfish, which ... Spaniard Germn Orizaola from the University of Uppsala (Sweden) ... a defensive response to the invasive species. They also ... with the crayfish. , Numerous invasive organisms are currently ...
(Date:7/9/2014)... antagonists can alleviate the symptoms of Alzheimer,s ... dysfunction and effectively scavenge amyloid beta peptide ... vaccines reduced and eliminated Aβ deposition in ... and significantly improved behavioral and cognitive impairment. ... Affiliated Hospital of China Medical University, China ...
(Date:7/9/2014)... it must first make a copy of its DNA, a ... billions of times a day in the human body. While ... cells use to replicate DNAthe enzymes that unzip the double-stranded ... picture of how the process works. , Now, researchers at ... what goes on at the "replication fork"the point where DNA ...
Breaking Biology News(10 mins):Frogs have developed rapid defences against the red swamp crayfish 2Frogs have developed rapid defences against the red swamp crayfish 3Rockefeller scientists first to reconstitute the DNA 'replication fork' 2Rockefeller scientists first to reconstitute the DNA 'replication fork' 3Rockefeller scientists first to reconstitute the DNA 'replication fork' 4
... With the heart having limited ability to regenerate following injury, ... in the developed world. Research impacting strategies for heart repair ... University of Houston (UH). Eric N. Olson, a ... will present "Heart Making and Heart Breaking: New Strategies for ...
... now a routine part of our nation,s weather forecast. Remarkably ... the Plains states and the West. The year also brought ... unusually warm winter meant little snowfall and bad news for ... events tell us about our changing climate? The Woods ...
... N.Y. A Cornell University scientist and designer from ... at the molecular level with insecticides for warding off ... 655,000 people annually on the continent. Though insecticide-treated ... African homes, the Cornell prototype garment can be worn ...
Cached Biology News:New heart repair strategies discussed at UH lecture May 15 2WHOI to host public forum on climate change and global water supplies 2African scientist, designer partner to fashion anti-malaria garment that wards off bugs 2
... that retain stiffness in liquids, protect against ... on each strip have chemically bonded dyes; ... provide clear comparison. Full-range strips (0 to ... of 100; each strip is approximately 1/4 ...
X-prolyl aminopeptidase (aminopeptidase P) 1, soluble...
This kit only detects beta-galactosidase activity at pH 6 in cultured cells andtissue sections. Beta-galactosidase activity at pH 6 ispresent only in senescent cells, and is not found inpresenescent...
... Since the Flp-In System creates isogenic ... equivalent levels of the protein of ... in Figure 3. In this experiment ... (CAT) was subcloned into pcDNA5/FRT and ...
Biology Products: